Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare neuroendocrine tumors. About 30% or more of them are thought to be of inherited origin due to germ-line mutations in at least 10 well-characterized genes. There are data linking specific genotypes of these tumors to specific locations, typical biochemical phenotypes or future clinical behaviors. Conversely, clinical features, catecholamine production and immunohistochemistry evaluation can help with the proper order of genetic testing for PHEO and PGL. The identification of a germ-line mutation can lead to an early diagnosis, appropriate treatment, regular surveillance and better prognosis not only for the patient but also for their family members. Moreover, the latest discoveries in molecular pathogenesis of these tumors will provide an important basis for future personalized therapy.
INTRODUCTION
Pheochromocytomas (PHEOs) are rare, usually benign tumors arising from catecholamine-producing chromaffin cells in the adrenal medulla. Tumors that arise from extra-adrenal chromaffin cells are classified as paragangliomas (PGLs). PGLs can originate in either the sympathetic or parasympathetic paraganglia. Sympathetic paraganglia have a thorax to pelvis distribution; parasympathetic paraganglia are mainly found in the head and neck and are usually termed head and neck PGL.
Previously, only 10% of cases were identified as being of inherited origin. According to the latest discoveries in the genetics of PHEO/PGL, about one-third of all these tumors are thought to be caused by germ-line mutations 1 in at least 10 genes. These genes include: REarranged during transfection (RET) protooncogene, Von Hippel-Lindau disease tumor-suppressor gene (VHL), neurofibromatosis type 1 tumor-suppressor gene (NF 1), genes encoding four succinate dehydrogenase complex (SDH) subunits (SDHx; that is, SDHA, SDHB, SDHC and SDHD genes), [2] [3] [4] gene encoding the enzyme responsible for flavination of the SDHA subunit (SDH assembly factor 2 (SDHAF2)) 5, 6 and newly described tumor-suppressor genes TMEM 127 7 and MAX. 8 Furthermore, there are data linking specific genotypes of these tumors to specific locations, typical biochemical phenotypes or future clinical behavior. [9] [10] [11] Conversely, clinical features, immunohistochemistry and catecholamine production can help with the proper order of genetic testing for PHEO/PGL. 12 (TABLE 1) RET proto-oncogene An activating germ-line mutation in the RET proto-oncogene is responsible for an autosomal-dominant syndrome multiple endocrine neoplasia type 2 (MEN 2). 2, 3 This syndrome is usually divided into three subgroups: MEN 2A is characterized by medullary thyroid carcinoma (MTC) in 95%, PHEO in 50% and hyperparathyroidism (caused by parathyroid hyperplasia/ adenoma) in 15-30% of cases. MEN 2B is characterized by MTC in 100%, PHEO in 50% of cases, marphanoid habitus, and multiple mucosal ganglioneuromas. The third group is represented by familial MTC that occurs alone. Approximately 90% of MEN 2 cases are of the MEN 2A subtype. RET proto-oncogene encodes a transmembrane-receptor tyrosine kinase involved in the regulation of cell proliferation and apoptosis. Many genotypephenotype correlations have been found in MEN 2.
CLINICAL AND LABORATORY FEATURES OF PHEO/PGL SUSPECTED GENES
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In MEN 2 patients, the PHEOs are usually adrenal, benign and bilateral in 450% of patients. 1, 2, 15, 16 The frequency of malignant transformation is o1-5%, but children with MEN 2B-associated PHEOs have a higher risk of malignancy compared with those with MEN 2A or sporadic disease.
14 PHEOs are most commonly diagnosed between 30 and 40 years of age. 1, 2, 14, 15, 16 In most cases, MTC is the first presentation of MEN 2, so PHEOs usually will not present as sporadic non-syndromic tumors. They often overexpress phenylethanolamine N-methyltransferase (the enzyme that converts norepinephrine to epinephrine), thus the biochemical phenotype is consistent with hypersecretion of epinephrine in large amounts. This is responsible for the increased plasma and urinary levels of the catecholamine O-methylated metabolite of epinephrine-metanephrine. 11, 12 VHL VHL encodes a Von Hippel-Lindau (VHL) protein, which by regulating the activity of hypoxia-inducible factor-alpha (HIF-a) controls various cellular processes and blood vessel formation. Loss of VHL protein function predisposes the VHL carriers to both benign and malignant tumors in multiple organs. VHL disease is an autosomal-dominant inherited syndrome with PHEOs/PGLs (VHL type 2) or without PHEOs/PGLs (VHL type 1) caused by germ-line mutations in VHL. PHEOs develop in 10-20% of VHL patients and may be early manifestations of VHL disease. Approximately 20% of VHL mutations arise de novo.
2,3,17,18 VHL type 1 is the most common form, with retinal angiomas, central nervous system hemangioblastomas, clear-cell renal carcinomas and other tumors like islet cell tumors of the pancreas, endolymphatic sac tumors, or cysts and cystadenomas of the kidney, pancreas, epididymis and broad ligament. VHL type 2 includes PHEOs/PGLs. Type 2A is without renal carcinomas, and other VHL type 1 tumors are infrequent; type 2B includes all VHL type 1 tumors; and type 2C develops PHEO alone, as an apparently sporadic non-syndromic tumor. 19 PHEOs of VHL patients are most commonly intra-adrenal (up to 50% bilateral or multiple tumors), although rarely sympathetic PGLs, and parasympathetic head and neck PGLs may be found too. VHL catecholamine-producing tumors are less frequently malignant than sporadic PHEOs (o5% of patients) with a mean age of presentation of 30 years. 1, 3, [14] [15] [16] [20] [21] [22] The biochemical profile of VHL patients differs from those with MEN 2 and neurofibromatosis type 1 (NF 1). VHL-associated PHEOs mostly produce only norepinephrine due to a low expression of phenylethanolamine N-methyltransferase, thus, patients usually show solitary increases in plasma and urinary normetanephrine levels. 11, 12 NF 1 NF 1, Von Recklinghausen's disease, is an autosomal-dominant genetic disorder caused by inactivating mutations of NF 1 tumorsuppressor gene (NF 1). This large gene encodes a neurofibromin, which is a GTPase-activating protein involved in the inhibition of RAS signaling cascade and mTOR (formerly mammalian target of rapamycin, now mechanistic target of rapamycin) kinase pathway, which controls cellular growth and differentiation. 23 Up to 50% of NF 1 germ-line mutations occur de novo. 2, 3 The clinical diagnosis of NF 1 requires at least two of the following criteria: six or more café -au-lait spots; two or more cutaneous neurofibromas or a plexiform neurofibroma; inguinal or axillary freckles; two or more benign iris hamartomas (Lisch nodules); at least one optic-nerve glioma; dysplasia of sphenoid bone or pseudoarthrosis; and a first-degree relative with NF 1. 24 PHEOs occur in 0.1-5.7% of patients with NF 1. 25, 26 In addition, other tumors like MTC, carcinoid tumors, parathyroid tumors, peripheral nerve sheath tumors and chronic myeloid leukemia have been described in NF 1 patients. 2, 26 The skin lesions typical for NF 1 usually lead to the diagnosis in childhood, whereas PHEOs are usually diagnosed in adulthood. 24 The mean age of PHEO diagnosis is in the fifth decade (42 years), the same as in the general population. In most cases, the PHEOs are benign and unilateral in the adrenal gland, although seldom bilateral PHEOs, and rarely extra-adrenal sympathetic PGLs may be seen. Malignant PHEOs have been identified in up to 12% of cases, similar to the frequency of malignancy in the general population. 1, 2, 15, 26, 27 Similar to RET-associated PHEOs, NF 1-related PHEOs produce more epinephrine and less norepinephrine. The increased plasma and urinary levels of metanephrine (indicating epinephrine overproduction) help to discriminate NF 1 patients from those with VHL and SDHx mutations. 11, 12 Genes encoding SDH Succinate dehydrogenase enzyme complex consists of four subunits encoded by four SDHx genes-SDHA, SDHB, SDHC and SDHD genes. For correct function of SDHA subunit, a cofactor of flavin adenine dinucleotide is necessary. SDHAF2 encoded by SDHAF2 gene (or SDH5, for its yeast ortholog) has the main role in flavination of SDHA. All these five genes (SDHA, SDHB, SDHC, SDHD and SDHAF2) can be involved in the development of PHEOs/ PGLs. [2] [3] [4] [5] [6] Inactivation of SDH is associated with the accumulation of succinate and increase in oxygen-free radical production (reactive oxygen species), resulting in the stabilization of HIF-a. Similarly as in VHL, HIF-a is not sufficiently degraded and the hypoxiadependent pathways are activated. HIF-a activates a wide variety of target genes (currently about 100-150 known genes), the products of which are implicated in the regulation of apoptosis, angiogenesis, energy metabolism, proliferation, migration and invasion of tumor cells. 28 Inactivating mutations of SDHD gene are responsible for familial PGL syndrome 1. 2, 3, 29 It is an autosomal-dominant syndrome characterized by familial parasympathetic head and neck PGLs, Germ-line mutations of SDHB gene are causative for familial PGL syndrome 4. It is an autosomal-dominant syndrome characterized by sympathetic extra-adrenal PGLs (usually solitary at the initial presentation), followed by adrenal PHEOs and parasympathetic head and neck PGLs. 1, 3, 15, 30, 32, 33 An increased risk for renal cell carcinoma, gastrointestinal stromal tumors, breast and papillary thyroid carcinomas in SDHB mutation carriers was previously described. [34] [35] [36] The mean age at diagnosis is approximately 30 years, varies from 6-77 years. Typically, SDHB-related PGLs originate in extra-adrenal locations (abdomen-the organ of Zuckerkandl, thorax-mediastinum, and pelvis). They are often large, mostly solitary and show a greater frequency of malignancy. SDHB gene mutations have been implicated as the most common cause in the pathogenesis of malignant PHEOs/PGLs in both children and adults.
1,9,10,15,30-32,37,38 SDHB-associated tumors have been observed to be malignant in 430% of cases. 1, 21, 30, 31, 39 All the patients with metastatic tumors should be considered for SDHB gene mutation testing. Diagnosis of SDHB-related PGLs is frequently delayed due to an atypical clinical presentation. Symptoms are caused by tumor mass effect rather than by excess catecholamine. 9, 31 No clear genotype-phenotype correlations have been detected for SDHB mutations. Because of low penetrance, they are often found in apparently sporadic patients. Identical SDHB mutations of family members may result in tumors of variable location, severity and behavior. 9, 32, 38, 39 SDHC gene mutations are causative for familial PGL syndrome 3. This rare autosomal-dominant syndrome is characterized by benign and seldom multifocal head and neck PGLs. [1] [2] [3] 15, 40 The mean age of onset is the same as in non-familial, sporadic cases. SDHC mutations were originally believed to be associated with parasympathetic head and neck PGLs only. 2, 41 However, extraadrenal sympathetic PGLs and PHEOs have also been reported. 1, 30 These tumors are typically benign, sometimes multiple.
Familial PGL syndrome 2 is a very rare autosomal-dominant syndrome characterized by familial head and neck PGLs. Most patients have multiple tumors. The mean age at presentation is between 30 and 40 years of age. No cases of PHEOs have been described yet. Hereditary transmission occurs exclusively in children of fathers carrying the gene, pointing to the importance of maternal imprinting. 32, 41 SDHAF2 has been identified as the causative gene. 5, 6 Results of recent studies suggest that SDHAF2 mutation screening should be considered in patients who suffer exclusively from head and neck PGLs, who have familial antecedents (high mutation penetrance) or a very young age of onset, multiple tumors and in whom SDHB, SDHC and SDHD gene testing was negative. 32 Initially, SDHA gene was thought to be associated only with a neurodegenerative disorder known as Leigh's syndrome, and not with PHEOs/PGLs. 3, 18 However, recent germ-line mutations of SDHA have been reported in several patients with PGLs (both sympathetic and parasympathetic) and one patient with PHEO. 4, 42 The current significance of SDHA mutation testing is less than moderate, but this may change if additional carriers are indentified. 32 The predominant biochemical phenotype of SDHx-related PHEOs/PGLs consists of dopamine hypersecretion alone or of both dopamine and norepinephrine (especially in SDHB-related tumors). 9 Thus, increased plasma levels of methoxytyramine (product of dopamine degradation) could discriminate patients with SDHx mutations from those with VHL, RET or NF 1 mutations. 11, 12 There is also another way to distinguish between SDHx and other germ-line mutation carriers. Immunohistochemistry staining for SDHB of removed tumors has been observed as a costeffective approach for discrimination of SDHx-related PHEOs/PGLs (negative staining due to the absence of SDHB is seen in SDHA, SDHB and SDHC; SDHD mutations may be weak diffuse or negative) from other forms (positive staining due to the presence of SDHB is seen in RET, VHL and NF1). 43, 44 The sensitivity and specificity of SDHB immunohistochemistry to detect the presence of SDHx mutation in prospective series were 100% and 84%, respectively. 44 Recently, immunohistochemistry staining for SDHA of 198 apparently sporadic PHEOs/PGLs found six cases (the negative staining due to absence of SDHA) with SDHA germ-line mutation only. 42 TMEM-127 gene Tumor-suppressor gene TMEM-127 encoding transmembrane protein 127 (TMEM-127) has been identified as a new PHEO susceptibility gene. 7 The function of TMEM-127 is not well defined. It has been linked to mTOR kinase. TMEM-127 dynamically associates with multiple endomembrane organelles, including endosomes, Golgi complex and lysosomes, suggesting a subcompartmental specific effect. It is possible that TMEM-127 contributes to modulation of mTOR kinase signaling by its association with components of the mTOR pathway within specific endosomal pools. 7, 32, 45 The association between TMEM-127 gene and mTOR kinase links it to other genes (RET and NF 1) with the kinase receptor signaling pathways (see below). In a large cohort of 990 individuals with PHEOs/PGLs, the frequency of TMEM-127 germ-line mutations was about 2%. Mean age at diagnosis was in the fifth decade (about 43 years). Typically, patients had benign (malignancy rate o5%) adrenal (bilateral in a third of patients) catecholamine-secreting PHEOs, with no preferential production of either norepinephrine or epinephrine. 46 However, recently, two cases of patients with extra-adrenal abdominal PGL and head and neck PGL have been reported. 47 Other tumors, including papillary thyroid carcinoma and breast cancer have been identified in TMEM-127 mutation carriers, but a causal relationship remains to be clarified. 45 MAX gene Protein MAX (also known as MYC-associated factor X) encoded by the MAX gene interacts with other transcription factors forming MYC-MAX-MXD1 network that regulates cell proliferation, differentiation and apoptosis. 48 MAX can function as both suppressor and activator of MYC oncoprotein and there is cross-talk between MYC-MAX-MXD1 network and the mTOR pathway involved in the development of PHEOs. Recent data suggests that MAX germ-line mutations are associated with PHEO susceptibility and that MAX behaves as a classic tumor-suppressor gene. 8 MAX-associated adrenal tumors are often bilateral (in 67%) and an association with malignant behavior was also found (in 25%). The mean age of onset was about 32 years. There are data suggesting paternal transmission of this tumor-susceptibility gene similar to SDHD or SDHAF2.
8 MAX mutations were recently found in patients with PGLs too (unpublished data).
Other genes related to PHEOs/PGLs Very rarely, patients with PHEO and neuroblastoma were reported in connection with germ-line mutations of kinesin family member 1B gene (KIF1B, located on chromosome 1p36.22). 49 This gene encodes a protein that induces apoptosis. It takes effect downstream of an oxygen-dependent prolyl hydroxylase (EGLN3/PHD3) with an important role in cell response to hypoxia and angiogenesis. [49] [50] [51] Genetics of pheochromocytoma D Karasek et al A germ-line mutation of the egl nine homolog 1 gene (EGLN1, also termed PHD2; located on chromosome 1q42.1) was detected in a family with congenital erythrocytosis and PGLs. 52 The gene product (EGLN1/PHD2) is a prolyl hydroxylase, member of the prolyl hydroxylases family, which has a crucial function in the oxygen-dependent proline hydroxylation of HIF-a and cell response to hypoxia. 50, 51 PHEOs/PGLs may also be a part of very rare syndromes (Carney triad syndrome and Carney-Stratakis syndrome). 35 PHEOs were reported very infrequently as a component of multiple endocrine neoplasia type 1.
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PATHOGENESIS OF HEREDITARY PHEOS/PGLS
There are probably two distinct groups of hereditary PHEOs/PGLs based on their transcription profile. Dahia et al. 53 identified two dominant expression clusters. The first cluster contained VHL and SDHx mutant tumors and the second contained RET and NF1 mutant tumors. Subsequent studies revealed that the transcription profile of PHEOs/PGLs with germ-line mutations in TMEM-127 and MAX cluster with the RET/NF1 group. 7, 8, 51 VHL/SDHx cluster showed a transcription profile associated with angiogenesis, hypoxia and a reduced oxidative response (so-called pseudohypoxic response) by stabilizing HIF-a. HIF-a is a transcription factor that activates several genes leading to dysregulation of apoptosis, angiogenesis, energy metabolism, proliferation, migration and invasion of tumor cells. 50 ,51 EGLN 1 germ-line mutations seem to belong to this group too, because EGLN 1 proteins take a main part in the degradation of HIF-a. 54 In contrast, RET/NF1 cluster covers genes involved in translation initiation, protein synthesis and kinase signaling. Activation of RET oncogene and inactivating mutations of NF1 are connected with activation of the RAS/RAF/MAPK pathway and the PI3/AKT signaling pathway. 51 Activation of mTOR in TMEM-127 mutations is a signal downstream of both RET and NF1 mutations via the PI3K/AKT pathway, possibly suggesting a common mechanism for mutations in RET, NF1 and TMEM-127.
7 Also MAX mutations have been counted among this gene cluster, because there is cross-talk between the MYC-MAX-MXD1 network and the mTOR pathway. 8, 51 Moreover, activation of the PI3K/AKT/mTOR and RAS/ RAF/MAPK signaling cascades may promote the degradation of MXD1, thereby inhibiting it from antagonizing MYC transcription activity. It is also well established that RAS/RAF/MAPK activation promotes MYC stability. 51 Nevertheless, another hypothesis presuming a single common pathway for different genes (RET, VHL, NF 1, SDHx and even KIF1B) has been proposed. 49, 55 According to this model, germ-line mutations of the above-mentioned genes allow neuronal progenitor cells to escape from c-Jun/EGLN3-dependent apoptosis, which is normally induced by loss of nerve growth factor during early development. These cells may serve as a base for forming PHEOs/PGLs in later life. 50, 51 Interaction between c-Jun and MYC may suggest potential role for MAX mutation in this model too. 56 However, this hypothesis does not provide an explanation for the two different transcription profiles and no links between EGLN 1 or TMEM-127 and neuronal apoptosis has still been found. 51 Despite these controversies in models for PHEO/ PGL molecular pathogenesis, discoveries in gene expression and the cellular pathways will likely provide a basis for potential personalized therapy in future.
CLINICAL IMPLICATION OF GENETIC TESTING FOR PHEOS/ PGLS
There are three main reasons for genetic testing. First, the familial syndromes are associated with other malignant tumors, so an early diagnosis of the syndrome (confirmed by the genetic testing) may lead to regular surveillance and early treatment. Second, hereditary forms of PHEOs are often multiple, extra-adrenal, recurrent and sometimes malignant, so a strict clinical follow-up is recommended for better prognosis of the patients. 17 Third, the identification of a germ-line mutation may also lead to early diagnosis, treatment and better prognosis for other family members through regular surveillance.
Personal, family history and clinical examination are starting points for the assessment of an appropriate germ-line mutation. In the case of a positive family history or evidence of specific features of the above-mentioned familial syndromes (Table 1) , targeted genetic testing should be performed. Germ-line mutations have been found in 100% of syndromic patients 1, 57 and in 41-64% of non-syndromic patients with positive familial history. 1, 58 Overall, about 90% of patients with positive familial history have a specific gene mutation. 1 However, the majority of PHEOs/PGLs are usually sporadic tumors without known family history or other symptoms of familial syndromes. Previous studies have shown that a significant number (7.5-27.0%) of patients with apparently sporadic PHEOs/ PGLs were carriers for germ-line mutations associated with familial syndromes. The frequency of genetic mutations in cases thought to be non-familial PHEOs/PGLs varied significantly (VHL 3.5-11.1%, RET 0.4-5.0%, SDHD 0.8-10.0% and SDHB 1.5-10.0%) and showed geographical differences. 59 Two large studies have found the frequency of germ-line mutations in non-syndromic patients with a negative family history of about 18-19%. 47, 48 But in the case of multiple or recurrent PHEOs/PGLs, the frequency has been estimated to be about 39%. 1 With the increasing number of tested genes, the frequency will be rising. According to these findings, it has been recommended that all patients with apparently sporadic PHEOs should be offered genetic testing. But routine testing for all known genes is too expensive and time consuming. Thus, various predictors for the genetic origin have been suggested. Based on results of several studies, the presence of a germ-line mutation is likely in patients with any of the following features: early onset (o45 years), bilateral, multifocal or extra-adrenal tumors (especially head and neck PGLs), recurrent or malignant disease and positive family history for PHEOs/ PGLs. 1, 15, 31, 41, 50, [57] [58] [59] And then the proper order of tested genes can also reduce the financial expenses. Patients with a positive familial history, personal history and/or presenting specific syndromic lesions should be tested for correspondent genes (Table 1) . Decision-making for gene testing of non-syndromic patients with apparently sporadic PHEOs/PGLs could be based on histological evaluation, localization and catecholamine production of the tumor-the 'rule of three'. 12 The situation may change in near future. By using the whole-genome sequencing, we can analyze all the PHEO-related genes in only one shot. The price of this method rapidly declines and many experts in the field believe that whole-genome sequencing will be economically feasible for routine use in medical care during the next 10 years.
Histological evaluation of PHEOs/PGLs Malignant PHEOs/PGLs (especially extra-adrenal PGLs) have been associated mostly with SDHB germ-line mutations (in 430% of cases). 9, 10, [30] [31] [32] [33] [34] [37] [38] [39] 51 Higher frequency of malignant PHEOs (in 25% of cases) was also detected in MAX germ-line mutations. 8 Malignant NF 1-related PHEOs were identified with similar frequency of malignancy (up to 12% of cases) like sporadic PHEOs in the general population. 1, 2, 15, [25] [26] [27] Less than 5% of malignant tumors have been described in carriers of RET, Biochemical phenotype Measurements of plasma metanephrine, normetanephrine and methoxytyramine (the O-methylated metabolites of catecholamines) can help to distinguish between some hereditary forms of PHEOs/PGLs. In contrast to patients with VHL, SDHB and SDHD mutations, Eisenhofer et al. 11 found all patients with RET-and NF1-related tumors characterized by increased plasma concentrations of metanephrine (indicating epinephrine production). VHL patients usually showed solitary increases in normetanephrine (indicating norepinephrine production), whereas additional or solitary increases in methoxytyramine (indicating dopamine production) characterized 70% of patients with SDHB and SDHD mutations. Patients with NF1 and MEN 2 could be discriminated from those with VHL, SDHB and SDHD gene mutations in 99% of cases by the combination of normetanephrine and metanephrine. Measurements of plasma methoxytyramine discriminated patients with SDHB and SDHD mutations from those with VHL mutations in an additional 78% of cases.
11
TMEM-127-associated PHEOs were described as catecholaminesecreting tumors, with no preferential production of either norepinephrine or epinephrine. 46 There are data connecting MAX germ-line mutations with increased plasma concentrations of metanephrine (unpublished observation).
CONCLUSION Currently, about 30% or more of PHEOs/PGLs are thought to be of inherited origin. They may be a part of the familial clinical syndromes or could be found alone as apparently sporadic tumors. There are probably two distinct groups of hereditary PHEOs/PGLs based on their transcription profile, which can explain some common features (catecholamine production, location and so on). Discoveries in molecular pathogenesis of PHEOs/PGLs will probably provide a basis for future personalized therapy. Today, genetic testing for germ-line mutation can help with correct and early diagnosis, appropriate treatment and better prognosis not only for the patient but also for other family members through regular surveillance. Decision-making for the proper order of potential mutations may be based on catecholamine production, location and histological evaluation of the tumor (Figure 1 ). 
CONFIRMED PHEO/PGL
BIOCHEMICAL PREDICTORS
If both normetanephrine and methoxytyramine are elevated then follow the algorithm for methoxytyramine. If both normetanephrine and metanephrine are elevated then follow the algorithm for metanephrine.
RET VHL NF1
Abbreviations: DA: dopamine; HNP: head and neck PGL; MTY: methoxytyramine. 
